38 results about "B type natriuretic peptides" patented technology

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and / or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The invention provides a human N-terminal pro-B-type natriuretic peptide (NT-proBNP) immunoassay kit, mainly comprising 1) a human NT-proBNP calibration material; 2) a vector coated with human NT-proBNP polyclonal antibodies; 3) an enzyme-labeling human NT-proBNP monoclonal antibody; and 4) an enzymatic chemical luminous substrate. The invention further provides a preparation method of the kit. On the basis of the kit of the invention, the enzyme-labeling human NT-proBNP monoclonal antibody, the human NT-proBNP polyclonal antibodies coated on the vector and human NT-proBNP antigens form a 'double-antibody sandwich' structure, thus effectively utilizing a chemiluminescence technical principle and guaranteeing detection sensitivity. In addition, the kit can be applied to an open chemiluminescence measuring instrument; and the kit has low use cost and easier popularization and application.

The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP). The disclosed invention relates to oxidized forms of B-type natriuretic peptide (BNP), which is useful as a marker for cardiovascular disease

The invention relates to a cardiac muscle control material, a preparation method therefor, a detection kit and a detection device for cardiac muscle. The cardiac muscle control material comprises quality control component and protection component, the quality control component comprises at least one of B-type natriuretic peptide, D-dimer, NT-proBNP, cardiac troponin I, myoglobin, creatine kinase isozyme and cardioid fatty acid binding protein and heart fatty acid binding protein. The protective component comprises 5 mM to 100 mM of a buffer agent, 0.5 % to 5% by weight of an excipient, 0.05 mMto 5 mM of an antioxidant, 0.05 mM to 15 mM of a protease inhibitor, 0.5% to 10% by weight of a stabilizer and 0.01% to 2% by weight of a surfactant. The cardiac muscle control material disclosed bythe invention is good in stability.

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and / or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

The invention discloses a competitive latex-particle-enhanced immunoturbidimetric assay kit for BNP (B-type natriuretic peptide) and a preparation method thereof, and solves the problems of high difficulty in BNP assay, long time for assay and the like in the current sandwich method. The kit disclosed by the invention is composed of latex particles and reaction buffer, and is characterized in that the latex particles are coated with the following artificially-synthesized amino acid sequences: FGRKMDR-X, and X consists of 2 to 4 Ks. The invention further provides a preparation method of the kit.. The kit disclosed by the invention has the advantages of high accuracy, short time for assay, high reliability, etc.

The invention discloses a method, system and chip test paper for parallel detection on various cardiac markers. The chip test paper is used for detecting a part or all of the cardiac markers including cTNI (cardiac troponin I), cTNT (cardiac troponin T), MYO (myoglobin), CK-MB (isoenzymeof creatine kinase containing M and B subunits), BNP (B-type natriuretic peptide), CRP (C-reactive protein) and FABP (fatty acid-binding protein); the chip test paper comprises a first membrane and a second membrane; a ligand An of each marker is arranged on the first membrane, and a ligand Bn coupled with a signal marker is absorbed on the second membrane; and a detected material forming sandwich detection together with the ligands An and Bn is added from a sampling hole, then under the acting force of percolation or other factors, the detected material moves to be combined with the ligands An and Bn respectively to form a composite array of the first membrane-the ligand An-the detected material-the ligand Bn-the signal marker, which is fixed on the first membrane, the composite array and a capture fiber membrane are assembled simultaneously, and a detection hole is reserved. The method, the system and the chip test paper provided by the invention can be used for detecting the various cardiac markers simultaneously and quantitatively; moreover, the detection sensitivity can be improved, and the detection time is saved.

The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects.Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

Methods and kits for characterizing the risk of developing cardiovascular disease are described. The methods include determining the levels of a plurality of risk predictors selected from the group consisting of B-type natriuretic peptide (BNP), myeloperoxidase (MPO), and high-sensitivity C-reactive protein (hsCRP) predictors in a biological sample from a subject. The levels of the plurality of risk predictors are then compared to corresponding control values to obtain a risk predictor differential for each risk predictor. The plurality of risk predictor differentials are then added to provide a cardiac biomarker score, and the cardiac biomarker score is compared to a reference biomarker score. A positive difference between the cardiac biomarker score and the reference biomarker score indicates the subject has an increased risk of developing cardiovascular disease compared to the risk of a reference population. The methods can be used for risk stratification.

The invention relates to a preparing method and application of an electrochemical luminescence sensor based on a silver oxalate bridging tris (bipyridine) ruthenium nanometer composite, and belongs tothe field of nanometer materials and analysis chemistry. A metal functionalization graphene oxide-silver oxalate / tris (bipyridine) ruthenium nanometer composite material and a ferroferric oxide poly-dopamine core-shell composite material are utilized to prepare the electrochemical luminescence sensor, and the electrochemical luminescence sensor is used for sensitity detection of N-terminal pro-B-type natriuretic peptide.

The invention relates to a human NT-proBNP preparation capable of stable preservation, a preparation method thereof, and a method for high-yield recombinant expression of human NT-proBNP; particularly, an escherichia coli expression system is used to produce a recombinant human B-type natriuretic peptide precursor (NT-proBNP), and the preparation process and conditions are optimized to obtain a preparation process for high-yield expression of human NT-proBNP; and the human NT-proBNP preparation capable of stable preservation is obtained by adding a stabilizing protective agent. The natural human NT-proBNP preparation prepared by adding the stabilizing protective agent in the invention can exist stably under conditions of -20 DEG C and -80 DEG C, and the biological activity is not decreased. A stable raw material source is provided for the preparation of NT-proBNP as a clinical diagnosis reagent standard substance and an antibody.

The invention relates to a preparation method and application of an electrochemical immunosensor based on palladium-doped molybdenum disulfide nanospheres, which belongs to the technical field of nanomaterials and electrochemical analysis. By adopting the electrochemical immunosensor prepared by molybdenum disulfide nanospheres modified by palladium nano particles doped cetyltrimethylammonium bromide, the high-sensitivity detection of N-terminal B-type N-terminal pro-brain natriuretic peptide is realized.

The invention relates to a preparation method for a microfluidic photoelectrochemical sensor for heart failure marker B-type natriuretic peptide, which comprises four parts of a microfluidic bottom plate, a microfluidic upper chip, a microfluidic lower chip, and a diaphragm between the upper chip and the lower chip, wherein the microfluidic upper chip includes electrode slots for accommodating a counter electrode, a reference electrode, a working electrode, an injection port and microchannel and a cleaning port and microchannel; the microfluidic lower chip comprises a working electrode slot and gas valve ports and microchannels; and three photoelectrochemical electrodes are integrated on the microfluidic sensor. By using the pump control, automatic detection can be realized, and an accurate detection result can be obtained quickly without human interference. The microfluidic photoelectrochemical sensor can realize fast, efficient, sensitive, and automated detection of B-type natriuretic peptides.

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and / or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

The invention discloses an N-terminal brain natriuretic peptide precursor detection kit and a detection method thereof. The kit comprises: reagents I: a phosphate buffer solution, a preservative, Tween 20 and polyethylene glycol; reagents II: a phosphate buffer solution, disodium hydrogen phosphate, sodium dihydrogen phosphate of 2 to 5 g / L, sodium chloride, a preservative and sensitized latex particles of a goat anti-human N-terminal-front B type natriuretic peptide antibody; and a calibration product: a phosphate buffer solution, bovine serum albumin, sodium chloride, a preservative and N-terminal-front B type natriuretic peptide antigen. According to the method, the test sensitivity is improved by applying a latex immunoturbidimetric method, the sensitized latex particles suitable for detecting an N-terminal front B type natriuretic peptide precursor are found, and the detection sensitivity is improved; large-batch samples can be detected quantitatively and simultaneously; and the kit comprises the calibration products and the quantitative detection aim is fulfilled.

The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects.The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

The present invention provides a bone repair promoter containing as an active ingredient at least one type of B-type natriuretic peptide receptor agonist.

It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped.The solution means of the present invention is an agent for the treatment of alopecia containing as an active ingredient a C-type natriuretic peptide (CNP), a B-type natriuretic peptide (BNP), a derivative of these NPs, a chimeric peptide of these NPs, or a derivative of a chimeric peptide of these NPs.

Described herein are methods for assessing the risk of cardiovascular disease in a subject in need thereof by detecting the presence of one or more cleavage products of the one or more natriuretic peptides over a period of time, wherein the presence of one or more cleavage products is indicative of an increased risk of the subject developing cardiovascular disease. Provided herein are compositions and kits comprising a non-natural natriuretic peptide comprising one or more D-amino acids. Also provided herein are methods of diagnosing a subject for a disease and treating the subject for the disease, wherein the method comprises the use of a non-natural natriuretic peptide comprising one or more D-amino acids.

The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis.

The invention provides a purpose of an agonist of natriuretic peptide receptor A (NPR-A) in pain management. Specifically, the invention relates to a purpose of the NPR agonist in the preparations of medicine compositions used for releasing or treating pains. Preferably the agonist is B-type natriuretic peptide (BNP) or atrial natriuretic peptide (ANP). The invention also relates to a medicine composition containing the NPR-A agonist, and a method for screening potential substances that can be used for releasing or treating pains. According to the method, for the first time, a relation between NPR-A mediated NPR-A / PKG / BKCa approach and pains is disclosed; and a medicine, a method and a purpose for treating, releasing or ameliorating pains through the regulation of the activation of the approach are provided.

The present invention provides a bone repair promoter containing as an active ingredient at least one kind of B-type natriuretic peptide receptor agonist.

The invention discloses a chemiluminiscence detection kit for a B-type natriuretic peptide precursor and a preparation method of the chemiluminiscence detection kit. The kit comprises magnetic particles coupled with a B-type natriuretic peptide precursor capture antibody, an acridinium ester labeled B-type natriuretic peptide precursor detection antibody, a B-type natriuretic peptide precursor system column standard substance, a chemiluminescence pre-excitation solution A, chemiluminescence excitation solution B and cleaning solution. The kit provided by the invention takes the magnetic separation chemiluminescence technology as a detection means, and is combined with the acridinium ester labeling technology at the same time. Compared with the existing technology for detecting the B-type natriuretic peptide precursor, the kit has the advantages of high sensitivity, high signal-to-noise ratio and rapid detection.

The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptidases.

The invention provides applications of drynaria fortune and drynaria fortune extract in prevention or treatment of heart failure. The drynaria fortune and the drynaria fortune extract can effectively reduce the heart weight index of a rat with heart failure, reduce levels of BNP (B-type natriuretic peptide), Ang II (Angiotensin II) and ALD (aldosterone) and remarkably improve the left ventricular systolic function of the rat with heart failure, thereby having the function of preventing or treating heart failure and having positive significance for development and utilization of Chinese herbal medicines, and a new scheme is provided for the treatment of the disease.

The invention provides a B-type natriuretic peptide detection kit. Based on colloidal gold immunoturbidimetry, the kit contains a reagent R2 which is a solution containing gold nanoparticles labeled with a B-type natriuretic peptide antibody. The kit is characterized in that particle size of the gold nanoparticles is 62.2nm-79.1nm; and the mass ratio of the gold nanoparticles to the antibody is 50:20-60. The invention also provides a preparation method of the kit. The kit provided by the invention has characteristics of high sensitivity, high specificity and good stability. No precipitate is generated after a reaction. It is convenient to clean a biochemical analyzer, and service life of the biochemical analyzer is prolonged.

The present invention relates to a kit for quantitatively detecting B-type natriuretic peptide, which includes immunomagnetic beads and a double-antibody sandwich fluorescence immuno-ELISA kit; the present invention also relates to a detection method for B-type natriuretic peptide, which uses the present invention kit for detection. The kit of the invention has high detection accuracy, strong specificity and high degree of automation. The kit and detection method of the invention are particularly suitable for rapid screening of B-type natriuretic peptide, and have broad application prospects.